Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
40 postmenopausal women, with a non-operated proximal humeral fracture, will be randomized to
standard treatment (physiotherapy) or standard treatment + Forsteo (rhPTH 1-34) during 4
weeks. Follow-up will be at 7 weeks and 3 months including x-ray and DASH score (The
Disabilities of the Arm, Shoulder and Hand) measuring physical function, and pain on a visual
analoge scale (VAS).
Two doctors, blinded to the treatment, will judge the callus formation and healing on the
x-rays and guess the treatment. The DASH score and the pain score will be compared between
the treatment groups.
The investigators hypotheses are that callus formation and healing will be more pronounced
and that patients have less pain and better function in the rhPTH 1-34 group.